Thyroxine hormone has been recognised since the early part of the nineteenth century and levothyroxine has been available since the midnineteenth century as a replacement for deficient thyroid hormones. While levothyroxine remains the staple treatment for hypothyroidism even to this day, its optimal use can be challenging. As is often the case with older drugs, the pharmacokinetics of levothyroxine is often underappreciated or misunderstood and many factors influence the optimal dosing of levothyroxine. This article will review the pharmacokinetics of levothyroxine in the treatment of hypothyroidism and highlight major concepts that should aid both clinicians and researchers.
T 4 and T 3 Production and Feedback Loop Mechanism
Normally, the hormones secreted by the thyroid are regulated by the hypothalamic-pituitary-thyroid (HPT) axis through a negative feedback system. Low levels of circulating T 4 and T 3 initiate the release of thyrotropin-releasing hormone (TRH) from the hypothalamus and thyroidstimulating hormones (TSH) from the pituitary. On interaction with its specific receptor, TSH stimulates the thyroid follicular cells to synthesise T 4 and T 3 and release them into the bloodstream. When circulating levels of T 4 and T 3 increase, they inhibit the release of TRH and TSH (i.e. negative feedback mechanism) thereby decreasing their own production. [1] [2] [3] [4] The predominant hormone produced by the thyroid gland is T 4 , with approximately 70-90 mcg of T 4 and 15-30 mcg of T 3 produced daily.
1,5 The production of the T 3 hormone by the thyroid gland is insufficient to meet the daily requirements of the organs in the body. Therefore, approximately 80 % of the body's required T 3 comes from peripheral conversion of T 4 to T 3 . 4, 6 Although both T 4 and T 3 are active, T 3 is more active as thyroid receptors within the cell nucleus have a 10-fold greater affinity for T 3 .
2,4

Indication and Dosage
Levothyroxine is a synthetic T 4 hormone that is biochemically and physiologically indistinguishable from the natural one, and it is administered when the body is deficient in the natural hormone. 7 Oral administration of levothyroxine is thus indicated for acquired primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic)
hypothyroidism. 8 It is also used to treat euthyroid goiters including thyroid nodules, subacute or chronic lymphocytic thyroiditis, multinodular goiter or for thyroid cancer patients who have undergone thyroidectomy, and as an adjunct to surgery and radioiodine therapy. 
Pharmacokinetic Properties
Major characteristics of levothyroxine PKs are summarised in Table 1 and are described in more detail below.
Absorption and Bioavailability
Levothyroxine is mainly absorbed in the small intestine, more specifically through the duodenum, jejunum and ileum. 10, 11 Very little is absorbed in the stomach. Consequently, patients with shorter small intestines (bowel resection) have reduced absorption and require higher levothyroxine doses. 12 The time to maximum concentration (Tmax) occurs at approximately 2 hours in euthyroid volunteers while it is delayed to approximately 3 hours in hypothyroid patients. 13 Food also delays Tmax.
13,14
The bioavailability of levothyroxine is approximately 60-80 % in euthyroid 
Volume of Distribution
Levothyroxine has a limited volume of distribution, which has been reported to be 11.6 litres (L) in euthyroid volunteers and 14.7 L in primary hypothyroid subjects. 19 This is approximately equivalent to the extracellular fluid volume of the body.
Metabolism
Although T 4 is subject to multiple metabolic reactions, 20-22 the main metabolic route for T 4 involves deiodination reactions (removal of iodine) by deiodinase enzymes. [23] [24] [25] Removal of iodine from the carbon 5 of the outer ring transforms T 4 to T 3 , thus T 4 can be regarded somewhat as a pro-hormone for T 3 .Deiodination of the inner ring of T 4 can also occur, leading to the formation of inactive reverse T 3 (rT 3 ).
Approximately half of deiodinised T 4 is metabolised to rT 3 and half to T 3 . 25, 26 Both T 3 and rT 3 are further metabolised to diiodothyronine (T 2 ), iodothyronamine (T 1 ) and reverse T 2 and T 1 .
25,26
Elimination
The daily turnover rate for T 4 is approximately 10 % while it is approximately 50-70 % for T 3 , with a slightly faster turnover rate in normal volunteers compared with patients with primary hypothyroidism. 
Transporters/Cytochrome Enzymes
Active transport of thyroxine into cells has been recognised for some time. 35, 36 In vitro studies have shown that organic anion transporting polypeptides (OATP) (such as OATP1A2, OATP1B1, OATP1C1, etc.), monocarboxylate transporter and sodium-taurocholate cotransporting polypeptide are involved at different levels.
37-41
However, few articles have been published on the in vivo significance of these transporters on the PK of levothyroxine. Lilja et al.
demonstrated the effects of the influx intestinal OATP transporter inhibition by grapefruit juice consumption on levothyroxine absorption. 42 They concluded that grapefruit juice had only a minor effect if any on levothyroxine absorption (AUC0-6 dropped by 9 % and Tmax was slightly delayed).
42
A transporter that may be induced by levothyroxine is PgP (ABCB1 gene). Jin et al. published results that showed that cyclosporine A trough concentrations were lower in patients taking levothyroxine. In addition, the expression of this transporter was increased and oral cyclosporine A concentrations and bioavailability were lower in rats treated with levothyroxine. 
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PK Properties in Special Populations
Renally Impaired Patients
The kidney plays a significant role in the peripheral metabolism of T 4 to T 3 . 1 Therefore, this metabolic route is significantly reduced in renally impaired patients, partially due to accumulated uremic toxins. 44, 45 In patients with renal disease, there is a reduction in total and free T 3 while T 4 is less affected; 46,47 however, some patients with end-stage The increased levothyroxine dose could also be due to drug-drug interactions with the medications patients are required to take after kidney transplantation.
47
Hepatically Impaired Patients
The liver is a major site for T 4 deiodination to T 3 . The clinical impact of severe cirrhosis on thyroid hormone levels is also influenced by other factors, such as lower levels of thyroxine binding proteins such as albumin. Overall, this possibly leads to an increase in free T 4 concentrations or the ratio of free T 3 to bound T 3 , meaning that despite overall lower levels of T 3 , more free T 4 and T 3 is available. Thus, because levothyroxine is a low-extraction drug, changes in protein binding will affect total levels but not free levels of hormone. Furthermore, increasing the dose of levothyroxine may not compensate for the lack of liver metabolism of T 4 to T 3 .
Obesity TSH values are increased in obese patients, which could be attributed to leptin, a hormone produced by adipose tissue that may increase TSH secretion. 61, 62 Therefore, in such patients, increased levels of TSH do not necessarily indicate hypothyroidism, and TSH should not be the only criteria used to adjust doses.
Some authors have reported higher circulating concentrations of T 4 and T 3 in obese patients while others have reported lower levels.
63,64
Santini et al. reported the lack of a correlation between serum leptin concentrations and the total dose of levothyroxine administered and that adipose tissue had a minor impact on levothyroxine requirements.
65
The authors also indicated that lean body mass was superior to actual weight as a predictor of dosage, which is in line with levothyroxine's small volume of distribution. Greater dose requirements in obese patients are probably attributed to a slightly higher volume of distribution (i.e.
higher lean body mass and peripheral mass) compared to non-obese patients rather than to a greater overall weight (fat weight). If weight is used to determine a starting dose in obese patients, total weight may lead to supra-therapeutic doses, therefore using lean body mass might be a better alternative. 
Pharmacokinetics of Levothyroxine in Special Populations
Bioavailability 73 The typical dose can be as high as 10-15 mcg/kg/day for infants from 0-3 months old and it decreases towards adulthood where the typical dose is 1.7 mcg/kg/day.
Elderly
In healthy elderly individuals, secretion of T 4 and T 3 and metabolism of T 4 to T 3 are reduced while rT 3 levels appear to increase.
74,75
Accordingly, the elimination half-life for T 4 is longer and reported to be 9.3 days in patients older than 80 years old. 76 Absorption of T 4 is also slightly lower for patients above 70. 77 Although T 4 concentrations do not appear to be decreased in older euthyroid patients, total and free T 3 concentrations are reportedly lower in individuals 61-90 years old compared with younger individuals 74 , which is expected due to their decreased metabolism. Therefore, measurements of only T 4 may be insufficient to explain changes in elderly patients' thyroid function.
Gastrointestinal Disorders
Certain gastrointestinal disorders, including celiac disease , can impede the absorption of levothyroxine.
As levothyroxine is mainly absorbed through the small intestine, its absorption is compromised in patients with coeliac disease. 78 Higher levothyroxine doses were reportedly required in patients with coeliac disease and when patients followed a gluten-free diet, levothyroxine dose requirement was reduced. 
Drug and Food Interactions
Many substances are known to influence T 4 or T 3 levels and the impact appears to be more significant in hypothyroid patients being treated with exogenous supplementation compared with patients without thyroid pathology, probably due to their intact feedback mechanisms.
In addition, interactions with levothyroxine can also occur indirectly via modulation of the HPT axis. All these will be described below and are summarised in Table 3 .
Food
The oral absorption of levothyroxine can be impaired by various 
Available Formulations
Commercial levothyroxine oral formulations available in North America and Europe include powders for intravenous solutions, tablets (e.g. There are advantages and disadvantages that are unique to the formulation type and not to levothyroxine per se. For instance, while tablets and capsules offer the advantage of precise dosing, solutions and liquids can be easier to swallow for children or the elderly.
Formulation differences that are specific to levothyroxine also exist.
The influence of pH on dissolution profiles of tablets and soft gel capsules is dissimilar, 162 as well as the negative impact of coffee intake on levothyroxine absorption.
93,94
Bioequivalence
The existence of multiple levothyroxine formulations is also the result of the availability of many generic versions of these compounds. Current regulatory guidelines published by the FDA recommend that bioequivalence of levothyroxine formulations be assessed by comparing PK measures of T 4 . 182 The underlying assumption regarding the use of T 4 rather than TSH or T 3 is that systemic T 4 levels reflect the levels at the site of action, and that a relationship exists between the efficacy and safety of the product and its systemic levels. Despite TSH sensitivity to changes in thyroid hormone level, TSH is not used to assess bioequivalence of thyroid formulations because it is a secondary response to levothyroxine and there is a significant time delay between the administration of exogenous levothyroxine and the changes noted in TSH levels. In addition, it is simply not a direct measure of levothyroxineadministered product, as are baseline-adjusted T 4 concentrations.
Because levothyroxine is an endogenous compound, it is important to take baseline levels into consideration when performing bioequivalence assessments to avoid biasing comparisons which can lead to failure in distinguishing true differences between formulations. 183 Current FDA bioequivalence guidelines require that supra-therapeutic doses of levothyroxine (600 mcg) be administered and that levothyroxine PK parameters be corrected for individual baseline values. This minimises the effect of endogenous concentrations on bioequivalence assessments 182, 184 by ensuring a high signal (concentrations related to exogenous levothyroxine) to noise (endogenous levels) ratio.
In addition to some of the recommendations described above, the FDA also stipulates that a levothyroxine product must have a 95-105 % potency specification over its entire shelf-life instead of previously accepted potency limits of 90-110 %. 185 This was established to ensure greater consistency in levothyroxine administered to patients and to reduce possibly large fluctuations in drug concentrations.
Thus, recommendations from current regulatory guidelines regarding study design and baseline adjustment of PK parameters ensure that a conservative approach to bioequivalence of levothyroxine formulations is adopted.
Summary
Although levothyroxine has long been a mainstay in the treatment of hypothyroidism, its optimal use often remains elusive. Not only are thyroid hormones levels governed by sensitive and complicated feedback mechanisms, but they are also subject to the influence of disease, the intake of food and the use of concomitant medication.
While these competing factors can pose a challenge for clinicians, a thorough comprehension of these elements as well as other PK considerations will ultimately be beneficial for the patient. n Chambers Jr J, Pittman C, Suda A, The effects of propranolol on thyroxine metabolism and triiodothyronines production in man, J Clin Pharmacol, 
